ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Surgeon’s Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Matthew Tollefson, Mayo Clinic, discussed a case of a 62 year old man with 3cm bladder tumor HG pT1 tumor with micropapillary features. Given the variant histology, there are concerns regarding aggressiveness and patients may choose from intravesical treatments to neoadjuvant chemotherapy followed by radical cystectomy to upfront radical cystectomy.

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Urologist Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Eugene Lee, University of Kansas, discussed the principles of surgery. Transurethral resection of the bladder tumor is of upmost importance. Resect all disease with wide margin with adequate muscle in the specimen. Examination under anesthesia provided vital information regarding concern for extravesical disease and pelvic fixation. Pathology report should have grade, stage with avoidance of ‘non-invasive’ in the report, documentation of whether muscle in specimen, histologic detail including presence or absence of lymphovascular invasion, CIS and/or variant histology.

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Radiation Oncology Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Ann Henry, University of Leeds, discussed bladder preservation strategies. Trimodality treatment with radical transurethral resection of bladder tumor (TURBT), chemotherapy and radiotherapy can have comparable outcomes to radical cystectomy.

ASCO GU 2017: Optimizing Outcomes in Muscle-Invasive and Metastatic Bladder Cancer - Session Highlights

Orlando, Florida USA (UroToday.com) Elizabeth Plimack, Fox Chase Cancer Center, discussed the molecular predictors of response to neoadjuvant chemotherapy. Predictive biomarker in indicative of outcome or invention or prognostic based on history.

ASCO GU 2017: Best of Journals: Prostate Cancer - Medical Oncologist Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Joshua Lang, University of Wisconsin, presented review of new molecular information in prostate cancer. Metastatic castrate-resistant prostate cancer (mCRPC) now has a multitude of regimens and sequence of administration to consider.

ASCO GU 2017: Best of Journals: Prostate Cancer - Radiation Oncologist Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Robert Den, Sidney Kimmel Medical College of Thomas Jefferson University, presented review of literature from a radiation oncologist perspective. The CHHIP trial assessed hypofractionation versus conventional IMRT with 3 arms 74Gy (standard) vs 60Gy or 57Gy (hypofractionated) regimens, respectively.

ASCO GU 2017: Best of Journals: Prostate Cancer - Surgeon's Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Jim C Hu, Cornell University, presented review best journal articles in prostate cancer. The PLCO study was re-examined with prior analyses highlighting contamination of 52% being a chief limiting factor deriving meaningful conclusions regarding survival outcomes.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe